Future of bioprocessing

What does the future hold?

Uppsala Bioprocess days 2019 brought experts from the biopharmaceutical industry together to focus on the future of bioprocessing. Key themes were process intensification, digitalization, and industrialization of cell and gene therapy. Explore articles and interviews with thought leaders discussing these topics.

mAb process intensification: Wei Gong, Henlius Biotech

Wei Gong, Director at Henlius Biotech, Shanghai shares key insights on implementing continuous bioprocessing in mAb manufacturing. She works with process development for downstream processes. In this video, you will get her views on the main opportunities and challenges for the industry.

Friday, March 27, 2020 | 00:03:29

mAb process intensification: Wei Gong, Henlius Biotech 00:03:29

Scaling up viral vector manufacturing: Carol Knevelman, Oxford BioMedica 00:03:34

Smarter and smaller biomanufacturing: Günter Jagschies 00:04:18

Emerging technologies in biomanufacturing: Lorenz Mayr 00:03:35

Cell and gene therapy manufacturing: Catarina Flyborg 00:04:00

Distribution of cell and gene therapies: Catarina Flyborg 00:02:54

Visions for the digitalization of biomanufacturing: Ben Newton 00:02:58

A continuous confidence boost

How do you implement a continuous strategy for GMP biomanufacturing? In this case study, Dr Wei Gong, Director at Shanghai Henlius Biotech, Inc. shares some impressive results on productivity and facility footprint gains. She also brings up some of the challenges they faced during the process.

Read article on continuous processing

Getting ahead of the game in cell and gene therapy

Carol Knevelman, Vice President, Head of Process R&D at Oxford BioMedica, shares a case study on large-scale lentiviral production. The study also covers how scale-up and supply chain challenges were addressed.

Read cell and gene therapy article

The future of biopharma—big needs and smart solutions

Günter Jagschies, former Senior Director, Strategic Customer Relations at GE Healthcare Life Sciences, makes a case why smarter and smaller facilities are the future of biomanufacturing. Also, Soon Jae Park, CEO of Alteogen, gives insight into the challenges of establishing a biosimilars business in South Korea.

Read article on the future of biopharma

How the industrial internet of things is transforming biomanufacturing

Jun Huan, Director Process Monitoring, Automation and Control at Pfizer, shares his views on digitalization in the biopharma industry and implementation of the industrial internet of things.

Read industrial internet article

The future of bioprocessing